Identification of patients at risk of ischemic events for long-term secondary prevention

Journal of the American Academy of Nurse Practitioners

Volumn 21, Issue 12, 2009, Pages 677-689

  Brassard, Andrea ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Atherothrombosis; Cerebrovascular disease; Continuum of care; Coronary heart disease; Peripheral arterial disease; Secondary prevention

Indexed keywords

ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

HEART MUSCLE ISCHEMIA; HUMAN; LIFESTYLE; METHODOLOGY; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION;

GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MYOCARDIAL ISCHEMIA; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING ASSESSMENT; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION;

EID: 72449149607     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2009.00444.x     Document Type: Review

References (90)

1. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators 1993). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342, 821 828.
2. Adams, R. J., Chimowitz, M. I., Alpert, J. S., Awad, I. A., Cerqueria, M. D., Fayad, P., et al. (2003). Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: A scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation, 108, 1278 1290. (Pubitemid 37099999)
3. Amarenco, P., Bogousslavsky, J., Callahan, A., 3rd., Goldstein, L. B., Hennerici, M., Rudolph, A. E., et al. (2006). High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 355, 549 559.
4. Ambriz, E. H., Woodard, L. D., Kressin, N. R., & Petersen, L. A. (2004). Use of smoking cessation interventions and aspirin for secondary prevention: Are there racial disparities? American Journal of Medical Quality, 19, 166 171.
5. Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., & Califf, R. M. (2007). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation, 116, e148 e304.
6. Antithrombotic Trialists' Collaboration 2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal, 324, 71 86.
7. Aronow, W. S., & Ahn, C. (1994). Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. American Journal of Cardiology, 74, 64 65. (Pubitemid 24196317)
8. Aronow, H. D., Novaro, G. M., Lauer, M. S., Brennan, D. M., Lincoff, A. M., Topol, E. J., et al. (2003). In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: A propensity analysis. Archives of Internal Medicine, 163, 2576 2582.
9. Baigent, C., Collins, R., Appleby, P., Parish, S., Sleight, P., & Peto, R. (1998). ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. British Medical Journal, 316, 1337 1343.
10. Barron, H. V., Viskin, S., Lundstrom, R. J., Wong, C. C., Swain, B. E., Truman, A. F., et al. (1997). Effect of beta-adrenergic blocking agents on mortality rate in patients not revascularized after myocardial infarction: Data from a large HMO. American Heart Journal, 134, 608 613.
11. Beta-Blocker Pooling Project Research Group 1988). The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients. European Heart Journal, 9, 8 16.
12. Bhatt, D. L., Chew, D. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2001). Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation, 103, 363 368.
13. Bhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., et al. (2007). Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology, 49, 1982 1988.
14. Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., et al. (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine, 354, 1706 1717.
15. Bhatt, D. L., Steg, P. G., Ohman, E. M., Hirsch, A. T., Ikeda, Y., Mas, J. L., et al. (2006). International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Journal of the American Medical Association, 295, 180 189.
16. Bianchi, C., Montalvo, V., Ou, H. W., Bishop, V., & Abou-Zamzam, A. M. (2007). Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Annals of Vascular Surgery, 21, 163 166.
17. Biviano, A. B., Rabbani, L. E., Paultre, F., Hurley, E., Sullivan, J., Giglio, J., et al. (2003). Usefulness of an acute coronary syndrome pathway to improve adherence to secondary prevention guidelines. American Journal of Cardiology, 91, 1248 1250.
18. Brass, L. M., Hartigan, P. M., Page, W. F., & Concato, J. (1996). Importance of cerebrovascular disease in studies of myocardial infarction. Stroke, 27, 1173 1176.
19. Budaj, A., Flasinska, K., Gore, J. M., Anderson, F. A., Dabbous, O. H., Spencer, F. A., et al. (2005). Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: Findings from a Global Registry of Acute Coronary Events. Circulation, 111, 3242 3247.
20. Burn, J., Dennis, M., Bamford, J., Sandercock, P., Wade, D., & Warlow, C. (1994). Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke, 25, 333 337.
21. Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., et al. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350, 1495 1504.
22. CAPRIE Steering Committee 1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329 1339.
23. Carswell, J. L., Beard, K. A., Chevrette, M. M., Pardue, C. N., Hess, D. C., & Fagan, S. C. (2004). Tracking trends in secondary stroke prevention strategies. Annals of Pharmacotherapy, 38, 215 219.
24. Chen, Z. M., Jiang, L. X., Chen, Y. P., Xie, J. X., Pan, H. C., Peto, R., et al. (2005). Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet, 366, 1607 1621.
25. Chen, J., Radford, M. J., Wang, Y., Marciniak, T. A., & Krumholz, H. M. (2000). Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Archives of Internal Medicine, 160, 947 952.
26. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., et al. (2003). Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 42, 1206 1252.
27. Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 363, 757 767.
28. Cooper, R., Cutler, J., Desvigne-Nickens, P., Fortmann, S. P., Friedman, L., Havlik, R., et al. (2000). Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention. Circulation, 102, 3137 3147.
29. Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., et al. (1992). Mortality over a period of 10 years in patients with peripheral arterial disease. New England Journal of Medicine, 326, 381 386.
30. De Backer, G., Ambrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., et al. (2003). European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on cardiovascular disease prevention in clinical practice. European Heart Journal, 24, 1601 1610.
31. de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A., White, H. D., et al. (2004). Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. Journal of the American Medical Association, 292, 1307 1316.
32. Diener, H. C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., et al. (2004). Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet, 364, 331 337.
33. Diener, H. C., Cunha, L., Forbes, C., Sivenius, J., Smets, P., & Lowenthal, A. (1996). European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences, 143, 1 13.
34. Dutch TIA Trial Study Group 1991). A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine, 325, 1261 1266.
35. Eagle, K. A., Kline-Rogers, E., Goodman, S. G., Gurfinkel, E. P., Avezum, A., Flather, M. D., et al. (2004). Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. American Journal of Medicine, 117, 73 81.
36. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events 2001). Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet, 357, 995 1001.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2001). Executive summary of the third report of The National Cholesterol Education Program (NCEP). Journal of the American Medical Association, 285, 2486 2497.
38. Farrell, B., Godwin, J., Richards, S., & Warlow, C. (1991). The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. Journal of Neurology, Neurosurgery & Psychiatry, 54, 1044 1054.
39. Fayad, P. (2006). Secondary prevention measures after a stroke - should they target stroke or heart disease? Nature Clinical Practice Neurology, 2, 646 647.
40. Ferrieres, J., Cambou, J. P., Cantet, C., & Guize, L. (2006). Prognosis at 6 months for coronary and cerebrovascular patients: Impact of antiplatelet agents and statins: Results from the Prevenir III study. Cardiovascular Drugs and Therapy, 20, 55 61.
41. Fox, K. A., Steg, P. G., Eagle, K. A., Goodman, S. G., Anderson, F. A., Granger, C. B., et al. (2007). Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. Journal of the American Medical Association, 297, 1892 1900.
42. Golomb, B. A., Dang, T. T., & Criqui, M. H. (2006). Peripheral arterial disease: Morbidity and mortality implications. Circulation, 114, 688 699.
43. Grines, C. L., Bonow, R. O., Casey, D. E., Gardner, T. J., Lockhart, P. B., Moliterno, D. J., et al. (2007). Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 115, 813 818.
44. Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., et al. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227 239.
45. Halkes, P. H., van Gijn, J., Kappelle, L. J., Koudstaal, P. J., & Algra, A. (2006). Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet, 367, 1665 1673.
46. Hankey, G. J. (2003). Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovascular Disease, 16 (Suppl. 1 14 19.
47. Hardie, K., Hankey, G. J., Jamrozik, K., Broadhurst, R. J., & Anderson, C. (2003). Ten-year survival after first-ever stroke in the Perth community stroke study. Stroke, 34, 1842 1846.
48. Heart Protection Study Collaborative Group 2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7 22.
49. Hippisley-Cox, J., & Coupland, C. (2005). Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: Nested case-control analysis. British Medical Journal, 330, 1059 1063.
50. Hirsch, A. T., Criqui, M. H., Treat-Jacobson, D., Regensteiner, J. G., Creager, M. A., Olin, J. W., et al. (2001). Peripheral arterial disease detection, awareness, and treatment in primary care. Journal of the American Medical Association, 286, 1317 1324.
51. Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., et al. (2006). ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation, 113, e463 e654.
52. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group 1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2, 349 360.
53. Kannel, W. B., Sorlie, P., & McNamara, P. M. (1979). Prognosis after initial myocardial infarction: The Framingham study. American Journal of Cardiology, 44, 53 59.
54. Khoury, Z., Schwartz, R., Gottlieb, S., Chenzbraun, A., Stern, S., & Keren, A. (1997). Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. American Journal of Cardiology, 80, 1429 1433.
55. Latini, R., Maggioni, A. P., Flather, M., Sleight, P., & Tognoni, G. (1995). ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation, 92, 3132 3137.
56. Lawes, C. M., Bennett, D. A., Feigin, V. L., & Rodgers, A. (2004). Blood pressure and stroke: An overview of published reviews. Stroke, 35, 776 785.
57. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group 1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349 1357.
58. Markus, H. S., Droste, D. W., Kaps, M., Larrue, V., Lees, K. R., Siebler, M., et al. (2005). Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation, 111, 2233 2240.
59. McDermott, M. M., Hahn, E. A., Greenland, P., Cella, D., Ockene, J. K., Brogan, D., et al. (2002). Atherosclerotic risk factor reduction in peripheral arterial disease: Results of a national physician survey. Journal of General Internal Medicine, 17, 895 904.
60. Mehta, R. H., Roe, M. T., Chen, A. Y., Lytle, B. L., Pollack, C. V., Brindis, R. G., et al. (2006). Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: Insights from the CRUSADE initiative. Archives of Internal Medicine, 166, 2027 2034.
61. Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., et al. (2001). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet, 358, 527 533.
62. Mosca, L., Appel, L. J., Benjamin, E. J., Berra, K., Chandra-Strobos, N., Fabunmi, R. P., et al. (2004). Evidence-based guidelines for cardiovascular disease prevention in women. Circulation, 109, 672 693. (Pubitemid 38198877)
63. Mouradian, M. S., Hussain, M. S., Lari, H., Salam, A., Senthilselvan, A., Dean, N., et al. (2005). The impact of a stroke prevention clinic in diagnosing modifiable risk factors for stroke. Canadian Journal of Neurological Sciences, 32, 496 500.
64. Mouradian, M. S., Majumdar, S. R., Senthilselvan, A., Khan, K., & Shuaib, A. (2002). How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke, 33, 1656 1659.
65. Nawarskas, J. J., & Spinler, S. A. (2000). Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors. Pharmacotherapy, 20, 698 710.
66. Ovbiagele, B., Saver, J. L., Fredieu, A., Suzuki, S., Selco, S., Rajajee, V., et al. (2004). In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke, 35, 2879 2883.
67. Pfeffer, M. A., Braunwald, E., Moye, L. A., Basta, L., Brown, E. J., Cuddy, T. E., et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine, 327, 669 677.
68. Practicing Clinicians Exchange 2008). Retrieved February 7, 2008, from http://www.practicingclinicians.com/index.html.
69. PROGRESS Collaborative Group 2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033 1041.
70. Qureshi, A. I., Suri, M. F., Guterman, L. R., & Hopkins, L. N. (2001). Ineffective secondary prevention in survivors of cardiovascular events in the US population: Report from the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine, 161, 1621 1628.
71. Radack, K., & Deck, C. (1991). Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Archives of Internal Medicine, 151, 1769 1776.
72. Rauch, U., Osende, J. I., Fuster, V., Badimon, J. J., Fayad, Z., & Chesebro, J. H. (2001). Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Annals of Internal Medicine, 134, 224 238.
73. Ringleb, P. A., Bhatt, D. L., Hirsch, A. T., Topol, E. J., & Hacke, W. (2004). Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 35, 528 532.
74. Rosamond, W., Flegal, K., Friday, G., Furie, K., Go, A., Greenlund, K., et al. (2007). Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 115, e69 e171.
75. Sabatine, M. S., Cannon, C. P., Gibson, C. M., Lopez-Sendon, J. L., Montalescot, G., Theroux, P., et al. (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New England Journal of Medicine, 352, 1179 1189.
76. Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., et al. (2006). Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, 37, 577 617. (Pubitemid 43732031)
77. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335, 1001 1009.
78. Sanossian, N., Saver, J. L., Liebeskind, D. S., Kim, D., Razinia, T., & Ovbiagele, B. (2006). Achieving target cholesterol goals after stroke: Is in-hospital statin initiation the key? Archives of Neurology, 63, 1081 1083.
79. Scandinavian Simvastatin Survival Study (4S) Group 1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383 1389.
80. Schwartz, G. G., Olsson, A. G., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D., et al. (2001). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. Journal of the American Medical Association, 285, 1711 1718.
81. Smith, S. C., Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., et al. (2006). AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology, 47, 2130 2139. (Pubitemid 44275145)
82. Smith, C. S., Cannon, C. P., McCabe, C. H., Murphy, S. A., Bentley, J., & Braunwald, E. (2005). Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. American Heart Journal, 149, 444 450.
83. Spertus, J. A., Kettelkamp, R., Vance, C., Decker, C., Jones, P. G., Rumsfeld, J. S., et al. (2006). Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation, 113, 2803 2809.
84. Steg, P. G., Bhatt, D. L., Wilson, P. W., D'Agostino, R., Ohman, E. M., Rother, J., et al. (2007). One-year cardiovascular event rates in outpatients with atherothrombosis. Journal of the American Medical Association, 297, 1197 1206.
85. Steinhubl, S. R., Berger, P. B., Mann, J. T., Fry, E. T., DeLago, A., Wilmer, C., et al. (2002). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. Journal of the American Medical Association, 288, 2411 2420.
86. Taneja, A. K., Collinson, J., Flather, M. D., Bakhai, A., de Arenaza, D. P., Wang, D., et al. (2004). Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). European Heart Journal, 25, 2013 2018.
87. Vickrey, B. G., Rector, T. S., Wickstrom, S. L., Guzy, P. M., Sloss, E. M., Gorelick, P. B., et al. (2002). Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke, 33, 901 906.
88. Viles-Gonzalez, J. F., Fuster, V., & Badimon, J. J. (2004). Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. European Heart Journal, 25, 1197 1207.
89. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine, 342, 145 153.
90. Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., & Fox, K. K. (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine, 345, 494 502.